alosetron has been researched along with Constipation in 28 studies
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.
Constipation: Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alosetron is indicated for women with chronic, severe diarrhea-predominant IBS (d-IBS) who have not responded adequately to conventional therapy." | 9.12 | A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. ( Ameen, V; Carter, EG; Gordon, SH; Heath, AT; Krause, R; Perschy, T; West, M, 2007) |
| "The aim of this study was to assess the effect of alosetron on bowel urgency and irritable bowel syndrome (IBS) global improvement in diarrhea-predominant IBS (D-IBS)." | 9.11 | Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. ( Ameen, VZ; Carter, EG; Gordon, SL; Heath, AT; Lembo, AJ; Olden, KW, 2004) |
| "Ischemic colitis and serious complications of constipation have been reported in association with the use of alosetron, which is approved for women with severe diarrhea-predominant IBS who have failed conventional therapies." | 8.83 | Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. ( Chang, L; Chey, WD; Harris, L; Olden, K; Schoenfeld, P; Surawicz, C, 2006) |
| "Alosetron is a potent, selective 5-HT(3) receptor antagonist prescribed for women with severe diarrhea-predominant irritable bowel syndrome (IBS-D) under a risk management plan (RMP)." | 7.76 | Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. ( Ameen, V; Chang, L; Tong, K, 2010) |
| "Alosetron users did not differ from IBS patients not using alosetron in the incidence of bowel surgery or hospitalized complications of constipation; there were no cases of colonic ischemia." | 7.72 | Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. ( Alfredson, T; Cook, SF; Miller, DP; Sands, BE; Walker, AM, 2003) |
| " Initial use was widespread, but infrequent serious adverse events of ischemic colitis and severe constipation-related complications prompted alosetron's voluntary withdrawal from the US market in November 2000." | 5.36 | Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. ( Lewis, JH, 2010) |
| "Because the mechanism(s) of drug-induced ischemic colitis and possibly other forms of intestinal ischemia associated with alosetron have not been elucidated, there is need to further assess risk with regard to patient susceptibility and other factors." | 5.33 | Alosetron: ischemic colitis and serious complications of constipation. ( Avigan, M; Brinker, A; Gallo-Torres, H, 2006) |
| "Alosetron is indicated for women with chronic, severe diarrhea-predominant IBS (d-IBS) who have not responded adequately to conventional therapy." | 5.12 | A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. ( Ameen, V; Carter, EG; Gordon, SH; Heath, AT; Krause, R; Perschy, T; West, M, 2007) |
| "The aim of this study was to assess the effect of alosetron on bowel urgency and irritable bowel syndrome (IBS) global improvement in diarrhea-predominant IBS (D-IBS)." | 5.11 | Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. ( Ameen, VZ; Carter, EG; Gordon, SL; Heath, AT; Lembo, AJ; Olden, KW, 2004) |
| "In irritable bowel syndrome with diarrhea, tricyclic antidepressants and alosetron are associated with a significant number needed to harm compared with rifaximin." | 4.88 | Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. ( Chong, K; Kim, S; Lembo, A; Pimentel, M; Shah, E, 2012) |
| "Ischemic colitis and serious complications of constipation have been reported in association with the use of alosetron, which is approved for women with severe diarrhea-predominant IBS who have failed conventional therapies." | 4.83 | Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. ( Chang, L; Chey, WD; Harris, L; Olden, K; Schoenfeld, P; Surawicz, C, 2006) |
| " Problems have arisen with alosetron being associated with ischaemic colitis and a high incidence of constipation." | 4.81 | Pharmacological treatment of irritable bowel syndrome--from concept to sales. ( Kamm, MA, 2002) |
| "Alosetron is a potent, selective 5-HT(3) receptor antagonist prescribed for women with severe diarrhea-predominant irritable bowel syndrome (IBS-D) under a risk management plan (RMP)." | 3.76 | Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. ( Ameen, V; Chang, L; Tong, K, 2010) |
| "Alosetron users did not differ from IBS patients not using alosetron in the incidence of bowel surgery or hospitalized complications of constipation; there were no cases of colonic ischemia." | 3.72 | Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. ( Alfredson, T; Cook, SF; Miller, DP; Sands, BE; Walker, AM, 2003) |
| "Alosetron (Lotronex) is a new therapeutic agent for irritable bowel syndrome (IBS) in women with diarrhea-predominant IBS." | 2.70 | Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. ( Chey, WY; Dukes, GE; Harding, J; Heath, AT; Hunt, CM; McSorley, DJ; Washington, MK; Wolfe, SG, 2001) |
| "Alosetron is a potent and highly selective serotonin 5-HT3 receptor antagonist which has been evaluated for the management of irritable bowel syndrome (IBS)." | 2.41 | Alosetron. ( Balfour, JA; Goa, KL; Perry, CM, 2000) |
| " Initial use was widespread, but infrequent serious adverse events of ischemic colitis and severe constipation-related complications prompted alosetron's voluntary withdrawal from the US market in November 2000." | 1.36 | Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. ( Lewis, JH, 2010) |
| "Because the mechanism(s) of drug-induced ischemic colitis and possibly other forms of intestinal ischemia associated with alosetron have not been elucidated, there is need to further assess risk with regard to patient susceptibility and other factors." | 1.33 | Alosetron: ischemic colitis and serious complications of constipation. ( Avigan, M; Brinker, A; Gallo-Torres, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (78.57) | 29.6817 |
| 2010's | 6 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Talley, NJ | 1 |
| Lewis, JH | 1 |
| Chang, L | 2 |
| Tong, K | 1 |
| Ameen, V | 2 |
| Mönnikes, H | 1 |
| Shah, E | 1 |
| Kim, S | 1 |
| Chong, K | 1 |
| Lembo, A | 2 |
| Pimentel, M | 1 |
| Cremonini, F | 1 |
| Nicandro, JP | 1 |
| Atkinson, V | 1 |
| Shringarpure, R | 1 |
| Chuang, E | 1 |
| Miller, DP | 1 |
| Alfredson, T | 1 |
| Cook, SF | 1 |
| Sands, BE | 1 |
| Walker, AM | 1 |
| Avigan, M | 2 |
| Justice, R | 1 |
| Mackey, AC | 1 |
| Nair, N | 1 |
| Koch, KM | 1 |
| Corrigan, BW | 1 |
| Manzo, J | 1 |
| James, CD | 1 |
| Scott, RJ | 1 |
| Stead, AG | 1 |
| Kersey, KE | 1 |
| Lembo, AJ | 1 |
| Olden, KW | 1 |
| Ameen, VZ | 1 |
| Gordon, SL | 1 |
| Heath, AT | 3 |
| Carter, EG | 2 |
| Kawano, K | 1 |
| Mori, T | 1 |
| Fu, L | 1 |
| Ito, T | 1 |
| Niisato, T | 1 |
| Yoshida, S | 1 |
| Shiokawa, S | 1 |
| Sato, Y | 1 |
| Murakami, H | 1 |
| Shishikura, T | 1 |
| Kamm, MA | 1 |
| Chey, WD | 1 |
| Harris, L | 1 |
| Olden, K | 1 |
| Surawicz, C | 1 |
| Schoenfeld, P | 1 |
| Gallo-Torres, H | 1 |
| Brinker, A | 1 |
| Krause, R | 1 |
| Gordon, SH | 1 |
| West, M | 1 |
| Perschy, T | 1 |
| Andresen, V | 1 |
| Montori, VM | 1 |
| Keller, J | 1 |
| West, CP | 1 |
| Layer, P | 1 |
| Camilleri, M | 3 |
| Balfour, JA | 1 |
| Goa, KL | 1 |
| Perry, CM | 1 |
| McColl, KE | 1 |
| Miller, JL | 1 |
| Shen, B | 1 |
| Soffer, E | 1 |
| Wolfe, SG | 1 |
| Chey, WY | 1 |
| Washington, MK | 1 |
| Harding, J | 1 |
| McSorley, DJ | 1 |
| Dukes, GE | 1 |
| Hunt, CM | 1 |
| Beck, IT | 1 |
| Lisi, DM | 1 |
8 reviews available for alosetron and Constipation
| Article | Year |
|---|---|
Quality of life in patients with irritable bowel syndrome.
Topics: Aged; Carbolines; Constipation; Diarrhea; Female; Gastrointestinal Agents; Health Status; Humans; Ir | 2011 |
Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
Topics: Alprostadil; Antidepressive Agents, Tricyclic; Carbolines; Constipation; Diarrhea; Gastrointestinal | 2012 |
Pharmacological treatment of irritable bowel syndrome--from concept to sales.
Topics: Antidepressive Agents; Benzofurans; Carbolines; Cisapride; Constipation; Drug Industry; Gastrointest | 2002 |
Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.
Topics: Carbolines; Clinical Trials as Topic; Colitis, Ischemic; Constipation; Diarrhea; Female; Gastrointes | 2006 |
Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Carbazoles; Carbolines; Constipation; Diarrhea; Dose-Response Relationship, Dr | 2008 |
Alosetron.
Topics: Adult; Animals; Area Under Curve; Biological Availability; Carbolines; Colonic Diseases, Functional; | 2000 |
The challenge of irritable bowel syndrome: creating an alliance between patient and physician.
Topics: Abdominal Pain; Antidepressive Agents; Antidiarrheals; Carbolines; Cholinergic Antagonists; Colonic | 2001 |
Novel medications for the irritable bowel syndrome: motility and sensation.
Topics: Abdominal Pain; Animals; Carbolines; Colonic Diseases, Functional; Constipation; Female; Gastrointes | 2001 |
5 trials available for alosetron and Constipation
| Article | Year |
|---|---|
Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.
Topics: Activities of Daily Living; Adult; Carbolines; Constipation; Diarrhea; Dose-Response Relationship, D | 2012 |
Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors.
Topics: Administration, Oral; Adult; Aging; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Arylamine N-Ace | 2004 |
Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
Topics: Adult; Carbolines; Constipation; Defecation; Diarrhea; Female; Gastrointestinal Agents; Humans; Irri | 2004 |
A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
Topics: Carbolines; Constipation; Diarrhea; Double-Blind Method; Drug Tolerance; Female; Gastrointestinal Ag | 2007 |
Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.
Topics: Carbolines; Colonic Diseases, Functional; Constipation; Double-Blind Method; Female; Humans; Male; S | 2001 |
15 other studies available for alosetron and Constipation
| Article | Year |
|---|---|
Board Review Vignette: Irritable Bowel Syndrome.
Topics: Abdominal Pain; Adult; Anion Exchange Resins; Antidiarrheals; Carbolines; Cholestyramine Resin; Cons | 2016 |
Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
Topics: Carbolines; Colitis, Ischemic; Constipation; Diarrhea; Dose-Response Relationship, Drug; Female; Hum | 2010 |
Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.
Topics: Adverse Drug Reaction Reporting Systems; Carbolines; Colitis, Ischemic; Constipation; Female; Humans | 2010 |
Alosetron (lotronex) revisited.
Topics: Carbolines; Colonic Diseases, Functional; Constipation; Cost-Benefit Analysis; Female; Humans; Produ | 2002 |
Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.
Topics: Adolescent; Adult; Aged; Carbolines; Child; Child, Preschool; Cohort Studies; Colon; Colonic Disease | 2003 |
Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.
Topics: Adverse Drug Reaction Reporting Systems; Carbolines; Clinical Trials as Topic; Colitis, Ischemic; Co | 2003 |
Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function.
Topics: Animals; Carbolines; Constipation; Diarrhea; Dogs; Gastrointestinal Motility; Gastrointestinal Tract | 2005 |
Alosetron: ischemic colitis and serious complications of constipation.
Topics: Carbolines; Colitis, Ischemic; Constipation; Gastrointestinal Agents; Humans; Irritable Bowel Syndro | 2006 |
Irritable bowel syndrome. New treatment drug on the market.
Topics: Carbolines; Colitis, Ischemic; Colonic Diseases, Functional; Constipation; Humans; Serotonin Antagon | 2000 |
Alosetron (Lotronex) for treatment of irritable bowel syndrome.
Topics: Carbolines; Colonic Diseases, Functional; Constipation; Dose-Response Relationship, Drug; Fees, Phar | 2000 |
Alosetron in irritable bowel syndrome.
Topics: Carbolines; Colonic Diseases, Functional; Constipation; Female; Humans; Quality of Life; Randomized | 2000 |
FDA draws patients into alosetron risk management.
Topics: Carbolines; Colitis, Ischemic; Colonic Diseases, Functional; Constipation; Contraindications; Drug L | 2000 |
Possible mechanisms for ischemic colitis during alosetron therapy.
Topics: Animals; Carbolines; Colitis, Ischemic; Constipation; Gastrointestinal Agents; Humans; Serotonin Ant | 2001 |
Safety concerns about alosetron.
Topics: Carbolines; Colitis, Ischemic; Constipation; Gastrointestinal Agents; Humans; Product Surveillance, | 2002 |
Lotronex withdrawal.
Topics: Carbolines; Colitis, Ischemic; Constipation; Gastrointestinal Agents; Humans; Product Surveillance, | 2002 |